Cyclophosphamid kardiotoxizität

Author: yutc

August undefined, 2024

WebApr 15, 2024 · In a retrospective analysis of 102 patients, et al. patient support program conducted between January 2011 and December 2012, 11 patients [1 woman; not all sexes stated] aged 38−62 years were described, who developed ejection fraction (EF) decreased or ventricular ectopic, manifested as cardiac toxicity, following the therapy with … WebCyclophosphamide (CP), also known as cytophosphane among other names, is a medication used as chemotherapy and to suppress the immune system. As …

Trofosfamide - an overview ScienceDirect Topics

WebAug 14, 2024 · The dose-limiting toxic effect of cyclophosphamide (CY) is cardiotoxicity. The pathogenesis of myocardial damage is poorly understood, and there is no established means of prevention. In previous studies, we suggested that for CY-induced cardiotoxicity, whereas acrolein is the key toxic metabolite, carboxyethylphosphoramide mustard … WebNov 1, 1986 · Patients who undergo bone marrow transplantation are generally immunosuppressed with a dose of cyclophosphamide (CYA) which is usually … laura thomas niehs

National Center for Biotechnology Information

WebDec 19, 2024 · Cyclophosphamide is an alkylating agent that is used for a variety of malignancies, including breast cancer, lung cancer, lymphomas, and in conditioning regimens before stem cell transplantation. High-dose cyclophosphamide (>1.5 g/m 2 /day) is considered to be highly cardiotoxic, with CTRCD incidences ranging from 7% to 28% ( … WebFeb 1, 2024 · CP-induced cardiotoxicity ranges from 7 to 28% and mortality ranges from 11 to 43% at the therapeutic dose of 170-180 mg/kg, i.v. CP undergoes hepatic … WebNov 18, 2012 · Es gibt keine Kontraindikation gegen die Kombination mit Cyclophosphamid, einer Substanz aus der Gruppe der Alkylantien. Eine Assoziation zwischen einer anthrazyklinhaltigen Chemotherapie und dem vermehrten Auftreten von Malformationen zeigte sich nicht. laura thompson azotech

[PDF] Cyclophosphamide cardiotoxicity: an analysis of dosing as …

Cyclophosphamide-Induced Cardiomyopathy: A Case Report, …

Webcyclophosphamide should be administered in the morning. 2.1 Dosing for Malignant Diseases Adults and Pediatric Patients . Intravenous When used as the only oncolytic drug therapy, the initial course of cyclophosphamide for patients with no hematologic deficiency usually consists of 40 mg per kg to 50 mg per kg given intravenously in WebCyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. M. Goldberg, J. Antin, +1 author J. Rappeport Published 1 November 1986 Medicine Blood Patients who undergo bone marrow transplantation are generally immunosuppressed with a dose of cyclophosphamide (CYA) which is usually calculated based on the patient's weight. laura thompson christiansburg vaWebJan 10, 2024 · Cyclophosphamide is a prodrug that requires an activation step by cytochromes (P450) in the liver [ 14 ]. As shown in Figure 1, the introduction of the hydroxyl group to the oxazaphosphorine ring … laura thompson cbc

"WebJul 4, 2024 · Other symptoms of cyclophosphamide toxicity include GI disturbances, alopecia, hemorrhagic cystitis, renal tubular necrosis, infertility, pulmonary fibrosis, and cardiotoxicity. The manifestation of … " - Cyclophosphamid kardiotoxizität

Cyclophosphamid kardiotoxizität

WebApr 11, 2024 · Cardiotoxicity means permanent damage to the muscles of the heart or the functioning of the heart. Cardiotoxicity can be severe with Adriamycin treatment and may develop late during therapy, or within two to three months after the treatment has ended. WebJun 26, 2015 · Cyclophosphamide (CY) is metabolized to 4-hydroxy-cyclophosphamide (HCY) in the hepatic cytochrome P-450 enzyme (CYP) system (CYP2B6 and/or CYP2C19). HCY enters cells as tautomer aldocyclophosphamide (AldoCY). Through β-elimination, AldoCY can be converted to phosphoramide mustard (PM) and acrolein.

Did you know?

WebThere are 6 disease interactions with cyclophosphamide. Myelosuppression Urinary tract obstruction Cardiac disease/cardiotoxicity Hepatic dysfunction Pulmonary impairment Renal dysfunction Major Cyclophosphamide (applies to cyclophosphamide) myelosuppression Major Potential Hazard, High plausibility. WebApr 15, 2024 · In a retrospective analysis of 102 patients, et al. patient support program conducted between January 2011 and December 2012, 11 patients [1 woman; not all …

WebSep 4, 2024 · CYC-related cardiotoxicity usually occurs in the first 3 weeks after drug administration. 6 Clinical presentation is an acute and severe congestive heart failure. WebJul 15, 2024 · Die Inzidenz der cyclophosphamidassoziierten Kardiotoxizität ist in der Literatur mit bis zu 28 % beschrieben, wenngleich der jeweilige Beitrag dieser Substanz im Rahmen von Kombinationstherapien gerade für das weit verbreitete Cyclophosphamid schwer zu definieren ist.

WebJan 1, 2013 · Cyclophosphamide has been used for several decades, but the pathophysiology of cyclophosphamide-induced cardiac toxicity remains poorly … WebMay 1, 1981 · Cardiotoxicity Associated With High-Dose Cyclophosphamide Therapy JAMA Internal Medicine JAMA Network Scheduled Maintenance Our websites may be …

WebHigh-dose cyclophosphamide also has cardiac adverse effects, and hepatic, respiratory, and sensory disorders occur in individual patients. Ifosfamide can cause potentially serious nephrotoxicity and extensive nerve dysfunction. Cardiovascular

WebFeb 1, 2024 · Cyclophosphamide and cardiotoxicity Cyclophosphamide is one of the potent alkylating agents used widely against rheumatoid arthritis, lupus erythematosus, … laura thompkinsWebFeb 7, 2024 · The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ann Hematol 2016; 95(7): 1145–1150. Crossref. PubMed. Google Scholar. 35. Duléry R, Mohty R, Labopin M, et al. Early cardiac toxicity associated with post-transplant ... laura thonn pwcWebMar 14, 2024 · Cyclophosphamide is an antineoplastic agent that has a broad range of therapeutic applications; however, it has numerous side effects, including cardiotoxicity. Furthermore, chili peppers contain a substance called capsaicin, having antioxidant and anti-inflammatory effects. laura thompson mdWebCyclophosphamide is a widely used anticancer and immunosuppressive prodrug that unfortunately causes severe adverse effects, including cardiotoxicity. Although the exact cardiotoxic mechanisms are not completely understood, a link between cyclophosphamide's pharmacologically active metabolites, name … laura thompson social worker liverpoolWebSep 7, 1991 · Cyclophosphamide (CY) cardiotoxicity may be a lethal complication of bone marrow transplantation. Previous echocardiographic studies have reported that left ventricular dysfunction due to CY occurs in over 50% of patients undergoing transplantation. laura thompson golf channelWebKardiotoxizität kann sich durch Herzrhythmusstörungen, arterielle Hypertonie, Thrombembolien, Angina pectoris, Myokardinfarkt und Herzinsuffizienz manifestieren. … laura thomson atlantaWebJan 22, 2024 · Other chemotherapy drugs that may cause cardiac toxicity are: Cyclophosphamide (Cytoxan ®) Fluorouracil (5-FU) Mitoxantrone (Novantrone ®) Cancer drugs that have been reported to cause abnormalities in heart rate or rhythm in more than 10% of patients include: Arsenic trioxide (Trisenox ®) Daunorubicin (Cerubidine ®) … laura thompson slater and gordon